Ultragenyx Pharmaceutical, Inc. (RARE) Receives a Buy from Wedbush
Wedbush analyst Laura Chico reiterated a Buy rating on Ultragenyx Pharmaceutical, Inc. (RARE) yesterday and set a price target of $75. The company’s shares closed last Monday at $59.69.
According to TipRanks.com, Chico has 0 stars on 0-5 star ranking scale with an average return of -6.2% and a 41.5% success rate. Chico covers the Healthcare sector, focusing on stocks such as Millendo Therapeutics Inc, Dova Pharmaceuticals Inc, and Prevail Therapeutics Inc.
Currently, the analyst consensus on Ultragenyx Pharmaceutical, Inc. is a Strong Buy with an average price target of $79.80, which is a 34.0% upside from current levels. In a report issued on August 1, J.P. Morgan also maintained a Buy rating on the stock with a $75 price target.
See today’s analyst top recommended stocks >>
Based on Ultragenyx Pharmaceutical, Inc.’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $99.17 million. In comparison, last year the company had a GAAP net loss of $52.73 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.